Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZV0203 in HER2-positive advanced solid tumors
NCT05423977Phase 1Enrolling by invitation
- Sponsor
- Hangzhou Adcoris Biopharmaceuticals
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZV0203 in HER2-positive solid tumor, sponsored by Hangzhou Adcoris Biopharmaceuticals. Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Started Dec 2021; status: enrolling by invitation.
02
Drugs
ZV0203
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT05423977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423977.